Abbott increases investment in SpectRx:
This article was originally published in Clinica
Executive Summary
Abbott Laboratories has increased its shareholding in the non-invasive glucose monitor developer, SpectRx, of Norcross, Georgia, by buying $2.75 million in preferred shares with a further $2.5 million commitment in January under the same terms. The revised agreement for the continuous monitoring device, presently in prototype form, gives Abbott exclusive worldwide marketing rights. SpectRx gets new milestones and will get a royalty on disposables when the product is eventually launched.